Nuvalent (NUVL) Other Non-Current Assets (2021 - 2026)
Nuvalent's (NUVL) quarterly Other Non-Current Assets came in at $23.2 million in Q1 2026, up 20.56% YoY from $19.3 million in Q1 2025, and up 14.46% on a QoQ basis from $20.3 million in Q4 2025.
Nuvalent (NUVL) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Nuvalent (NUVL) has 6 years of Other Non-Current Assets data on file, last reported at $23.2 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 20.56% year-over-year to $23.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.2 million (up 20.56% YoY) and the FY2025 annual result came in at $20.3 million, up 117.96% from the prior year.
- Other Non-Current Assets rose to $23.2 million in Q1 2026, from $20.3 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $23.2 million in Q1 2026 to a low of $2.6 million in Q1 2022.
- A 5-year average of $10.6 million and a median of $9.0 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets gained 18.03% — and 2025, when it soared 150.08%.
- Tracing NUVL's Other Non-Current Assets over 5 years: stood at $4.5 million in 2022, then jumped by 31.96% to $5.9 million in 2023, then surged by 57.8% to $9.3 million in 2024, then surged by 117.96% to $20.3 million in 2025, then grew by 14.46% to $23.2 million in 2026.
- The last three Other Non-Current Assets figures came in at $23.2 million (Q1 2026), $20.3 million (Q4 2025), and $23.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | 23.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.21 Mn |
| Dec 31, 2025 | 20.28 Mn |
| Sep 30, 2025 | 22.97 Mn |
| Jun 30, 2025 | 20.93 Mn |
| Mar 31, 2025 | 19.25 Mn |
| Dec 31, 2024 | 9.30 Mn |
| Sep 30, 2024 | 9.18 Mn |
| Jun 30, 2024 | 8.97 Mn |
| Mar 31, 2024 | 8.97 Mn |
| Dec 31, 2023 | 5.90 Mn |
| Sep 30, 2023 | 5.31 Mn |
| Jun 30, 2023 | 4.96 Mn |
| Mar 31, 2023 | 4.70 Mn |
| Dec 31, 2022 | 4.47 Mn |
| Sep 30, 2022 | 4.31 Mn |
| Jun 30, 2022 | 4.20 Mn |
| Mar 31, 2022 | 2.57 Mn |
| Dec 31, 2021 | 3.20 Mn |
| Sep 30, 2021 | 2.83 Mn |
| Jun 30, 2021 | 2.50 Mn |